TAPT1

Across TCGA pan-cancer cohorts, TAPT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAPT1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAPT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TAPT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where TAPT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.795	0.378	<.001	66	view →
HNSC	DFS	Quartile	II,III,IV	0.869	1.000	.014	8	view →
LSCC	OS	Tertile	III,IV	0.855	0.433	.013	4	view →
LUAD	OS	Tertile	III,IV	0.750	0.294	.044	2	view →
PDAC	OS	Quartile	III,IV	0.927	0.445	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAPT1–CCRCC (DFS)

Open the CCRCC breakdown →